Cargando…
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
AIM: To investigate the impact of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on the risk of incident heart failure and adverse cardiovascular outcomes. METHODS: All patients with diabetes who were registered between January 2018 and December 2019 were identified from a federated electronic me...
Autores principales: | Fawzy, Ameenathul Mazaya, Rivera‐Caravaca, José Miguel, Underhill, Paula, Fauchier, Laurent, Lip, Gregory Y. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087187/ https://www.ncbi.nlm.nih.gov/pubmed/36054168 http://dx.doi.org/10.1111/dom.14854 |
Ejemplares similares
-
Atrial Fibrillation and the Risk of Ventricular Arrhythmias and Cardiac Arrest: A Nationwide Population-Based Study
por: Fawzy, Ameenathul M., et al.
Publicado: (2023) -
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021) -
Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis
por: Li, Hang-Long, et al.
Publicado: (2021) -
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)